

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED
華康生物醫學控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 8622)

CHANGE OF AUDITOR

This announcement is made pursuant to Rule 17.50(4) of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”).

The board (the “**Board**”) of directors (the “**Directors**”) of Huakang Biomedical Holdings Company Limited (the “**Company**”) announces that Deloitte Touche Tohmatsu (“**Deloitte**”) has resigned as the auditor of the Company (the “**Auditor**”) with effect from 19 December 2019. Deloitte stated in their letter of resignation that, as part of their normal procedures which include an annual consideration of whether they would continue to act for their audit clients, having taken into account factors including the level of audit fees, their available internal resources in the light of current work flows and the professional risk associated with the audit, they decided to tender their resignation as the auditor of the Company.

Deloitte has confirmed in its resignation letter that there are no matters in connection with its resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or creditors of the Company. The Board and the audit committee of the Company (“**Audit Committee**”) confirmed that there is no disagreement between the Company and Deloitte and that there are no other matters or circumstances in connection with the change of Auditor that need to be brought to the attention of the Shareholders or the creditors of the Company.

The Board would like to take this opportunity to express its sincere gratitude to Deloitte for its professional services rendered to the Company in the past years.

APPOINTMENT OF AUDITOR

The Board further announces that with the recommendation from the Audit Committee, Mazars CPA Limited (“**Mazars**”) has been appointed as the new Auditor with effect from 19 December 2019 to fill the casual vacancy following the resignation of Deloitte and to hold office until the conclusion of the next annual general meeting of the Company. The Board has confirmed that it is not aware of any

matters in relation to the appointment of Mazars that need to be brought to the attention of the Shareholders or creditors of the Company. The Board wishes to extend its warmest welcome to Mazars on its appointment as the Auditor.

By order of the Board
HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED
ZHANG Shuguang
Chairman and Executive Director

Hong Kong, 19 December 2019

As at the date of this announcement, the Executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang and Mr. Poon Lai Yin Michael; and the Independent Non-executive Directors are Dr. Yeung David Wai Chow, Mr. Kwok Chi Shing and Mr. Chan Kin Sang.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least seven days from the date of publication and on the Company’s website at www.huakangbiomedical.com.